PROCEPT BioRobotics (NASDAQ:PRCT) and Shandong Weigao Medical Polymer (OTCMKTS:SHWGF) Head to Head Comparison

PROCEPT BioRobotics (NASDAQ:PRCT) and Shandong Weigao Medical Polymer (OTCMKTS:SHWGF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares PROCEPT BioRobotics and Shandong Weigao Medical Polymer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
Shandong Weigao Medical Polymer	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for PROCEPT BioRobotics and Shandong Weigao Medical Polymer, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2	10	3	1	2.19
Shandong Weigao Medical Polymer	0	1	0	0	2.00

PROCEPT BioRobotics presently has a consensus target price of $28.00, suggesting a potential upside of 29.15%. Given PROCEPT BioRobotics’ stronger consensus rating and higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Shandong Weigao Medical Polymer.

Risk and Volatility

PROCEPT BioRobotics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Shandong Weigao Medical Polymer has a beta of -0.24, meaning that its stock price is 124% less volatile than the S&P 500.

Institutional & Insider Ownership

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares PROCEPT BioRobotics and Shandong Weigao Medical Polymer”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05 million	4.03	-$95.57 million	($1.94)	-11.18
Shandong Weigao Medical Polymer	$1.82 billion	1.06	$314.90 million	N/A	N/A

Shandong Weigao Medical Polymer has higher revenue and earnings than PROCEPT BioRobotics.

Summary

PROCEPT BioRobotics beats Shandong Weigao Medical Polymer on 8 of the 13 factors compared between the two stocks.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About Shandong Weigao Medical Polymer

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers single use medical consumables and materials, including infusion sets, syringes, blood bags and blood component segregators consumable, blood sampling products, prefilled syringes for pre-pack medication and medical needles which mainly include intravenous needles, syringe needles, intravenous catheter needles, blood sampling needles and irregular needles; orthopedic materials and instruments, including trauma products of steel plates and screws, spinal implants, and artificial joints; and blood purification consumables and equipment, including puncture needles, extracorporeal blood circuit for blood purification sets, dialyzers and related consumables. It also provides tumour and blood vessel interventional instruments; flushing syringes; blood collection, irradiation, storage, separation and sterilization products; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; medical polymer materials and products; injection puncture Instruments; medicines; and X-ray based irradiation machines. In addition, it is involved in the finance leasing and factoring business; provision of enterprise management advisory services, logistics and storage, and computer technical services; and sale of electronic products. The company was incorporated in 2000 and is based in Weihai, the People’s Republic of China.